NONOF - Medicare coverage for obesity drugs could strain federal budget: CBO
2024-03-20 13:09:31 ET
More on Eli Lilly, Novo Nordisk, etc.
- Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront
- Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified
- Eli Lilly and Co (LLY) Cowen's 44th Annual Health Care Conference (Transcript)
- NASH drug market expected to surpass $48B by 2035
- Eli Lilly Zepbound prescriptions exceed Novo’s Wegovy for the first time in U.S.